I’m not looking to buy AMGN under any circumstances, although I can see how it might turn out OK when the current story has run its course.
Longer term, I’m bearish on AMGN because they are the most vulnerable to the advent of biogenerics and I do not think this eventuality has been fully factored into the share price. Many investors seem to think Big Biotech will be able to block biogenerics indefinitely, but I’m pretty sure they are wrong. Regards, Dew
News 
Market Data 
Discover 
AI
